{"id":40034,"date":"2021-02-24T07:27:05","date_gmt":"2021-02-24T07:27:05","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=40034"},"modified":"2021-02-26T16:31:38","modified_gmt":"2021-02-26T16:31:38","slug":"russian-sputnik-vaccine-reports-91-efficacy-at-21-days-after-the-first-dose","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/40034","title":{"rendered":"Russian Sputnik vaccine reports 91% efficacy at 21 days after the first dose"},"content":{"rendered":"<p><b><strong><span lang=\"EN-US\"><img loading=\"lazy\" decoding=\"async\" class=\" alignright\" src=\"https:\/\/i-base.info\/wp-content\/uploads\/2020\/03\/COVID-19-graphic.png\" width=\"231\" height=\"142\" \/><\/span><\/strong>Simon\u00a0Collins,\u00a0HIV\u00a0i-Base<\/b><\/p>\n<p><strong>On 2 February 2021, early interim phase 3 efficacy result from the Russian recombinant adenovirus-based vaccine, Gam-COVID-Vac (Sputnik V) were published in the Lancet. [1]<\/strong><\/p>\n<p>This double-blind, placebo-controlled study randomised 21,977 adults between 7 September and 24 November 2020 to either the vaccine (n=16\u2008501) or placebo (n=5476) groups. [2]<\/p>\n<p>The vaccine was developed by the Gamaleya Research Institute in Moscow and the study was run at 25 hospitals in Moscow.<span class=\"Apple-converted-space\">\u00a0 <\/span>The study involves a prime boost vaccination schedule using two vaccinations, three weeks apart. However, the primary endpoint in this interim analysis \u2013<span class=\"Apple-converted-space\">\u00a0<\/span>called to determine whether sufficient early efficacy could limit the need for further use of a placebo arm during a growing COVID-19 crisis \u2013<b>\u00a0<\/b>was confirmed COVID-19 infection 21 days after the first vaccine (ie when the second vaccine was given).<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p>Baseline characteristics included 61% male, 98% Caucasian and 35% were &gt;50 years old.<\/p>\n<p>Based on 16 (0.1%) vs 62 (1.3%) confirmed cases in the active vs placebo groups, the paper reported 91.6% efficacy (95% CI: 85.6 to 95.2).<\/p>\n<p>Tolerability was good with most adverse events reported as grade 1. None of the more erious events (45 vs 23; 0.3 vs 0.4%) were judged to be vaccine related.<\/p>\n<p>References<\/p>\n<ol>\n<li>Logunov DY et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 397(10275)p671-681. DOI: 10.1016\/S0140-6736(21)00234-8. (20 February 2021).<br \/>\n<a href=\"https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(21)00234-8\/fulltext\">https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(21)00234-8\/fulltext<\/a><\/li>\n<li>clinicaltrials.gov. Clinical trial of efficacy, safety, and immunogenicity of Gam-COVID-Vac vaccine against COVID-19 (RESIST).<br \/>\n<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04530396\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04530396<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Simon\u00a0Collins,\u00a0HIV\u00a0i-Base On 2 February 2021, early interim phase 3 efficacy result from the Russian recombinant adenovirus-based vaccine, Gam-COVID-Vac (Sputnik V) were published in the Lancet. [1] This double-blind, placebo-controlled study randomised 21,977 adults between 7 September and 24 November 2020 &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[292,278],"tags":[],"class_list":["post-40034","post","type-post","status-publish","format-standard","hentry","category-covid-19-vaccine","category-covid-19"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/40034","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=40034"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/40034\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=40034"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=40034"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=40034"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}